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Objective: To identify the risk factors of HIV vertical transmission in
pregnant women.
Study Design: Observational cohort study. Between 2002 and 2003,
479 HIV-infected pregnant women in a PMTCT (prevention of the
mother-to-child transmission) program were followed up with their
infants at delivery, until 15 months with infant HIV testing.
Results: Of these 281 infants had a deﬁnitive HIV result by 15 months of
age, and 31.7% of the infants become HIV infected. In univariate analysis
the risk factor identiﬁed were presence of vaginal discharge, genital
itchiness, genital ulcers, dysuria, abnormal breast and vaginal infections
(Trichomonas, Bacteria vaginosis and Candida) in the mother at
enrolment. In multivariate analysis vaginal infections risk ratio (RR)
1.72(1.03–2.88) and abnormal breast RR 4.36(2.89–6.58) were
predictors of HIV vertical transmission.
Conclusion: There is need to screen for vaginal infections
(Trichomonas, Bacteria vaginosis and Candida) and examine pregnant
women for mastitis to identify women at risk of HIV vertical transmission
for prevention.
Journal of Perinatology (2010) 30, 717–723; doi:10.1038/jp.2010.31;
published online 25 March 2010
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Introduction
In resource-limited settings, the rate of mother-to-child
transmission of human immunodeﬁciency virus (HIV) infection
can reach as high as 40%, particularly with prolonged
breastfeeding.
1 The majority (90%) occur in sub-Saharan Africa.
2
Current approaches to reduce this transmission involve
antiretroviral drugs given during pregnancy, at delivery and
postnatally to the infant. In poor communities, short-course
regimens based on single-dose nevirapine to the mother and infant
are being used.
3
In 2007, Zimbabwe had about 7 million people in the
reproductive age (15 to 49 years) with a total fertility rate of
3.3 children per woman.
4 Estimated adult HIV prevalence was
15% and only 29% of HIV-infected pregnant women received
antiretroviral prophylaxis as part of the Prevention of the mother-
to-child transmission (PMTCT) of HIV national program.
4 The
single-dose nevirapine regimen was being used in the national
program at this time. The estimated HIV prevalence in pregnant
women was 25.7% in 2002, and although it has dropped to 17.7%
in 2006, the prevalence remains high.
5 With such a high prevalence
of HIV and limited access to antiretroviral prophylaxis, it becomes
important to identify risk factors of mother-to-child transmission
of HIV in this setting where prevention is still a problem and early
infant diagnosis is still a challenge. Factors that have been identiﬁed
in other settings might not be relevant in this resource-poor setting,
and therefore an assessment of various risk factors of HIV vertical
transmission was performed among a cohort of women and infants
who participated in a PMTCT program in Zimbabwe.
Methods
Setting
The study was conducted at three primary maternal and child
health clinics in peri-urban areas around the capital city of Harare,
(namely Epworth, Seke North and St Mary’s) in Zimbabwe.
Design
This was a prospective observational cohort study of mother and
child pairs followed up for 15 months. Between April 2002 and
November 2003 HIV-infected pregnant women were enrolled into the
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Pre- and post-test HIV counseling was offered as part of the national
PMTCT program. Baseline information included sociodemographic
characteristics, medical history of sexually transmitted infections,
gynecological examination ﬁndings, vaginal swabs and blood
sampling for full blood counts and serology for sexually transmitted
infections, namely syphilis and herpes simplex type-2. Mothers were
to receive 200mg nevirapine in labor and their infants were to
be given nevirapine 2mgkg
 1 body weight within 72h of delivery
according to the national guidelines (HIVNET 012).
3
Follow-up
From delivery, mother and child pairs were followed up until
15 months post-delivery. This was an overall breastfeeding cohort
of infants in whom breastfeeding patterns were documented.
In addition to infant blood sampling for HIV testing at delivery,
6 weeks, 4 months, 9 months and 15 months, infants were assessed
for signs and symptoms of AIDS by a pediatrician. The time points
coincided with the infant vaccination schedule in Zimbabwe.
Feeding history was obtained from the caregivers. All HIV-exposed
infants were provided with cotrimoxazole prophylaxis until their
deﬁnitive HIV status was known. This was done mainly to prevent
Pneumocystis carinii pneumonia, which is a major cause of early
mortality among HIV-infected infants.
6 All HIV-infected infants
were referred to the appropriate pediatric HIV/AIDS clinics for care
according to the national guidelines. At this time, antiretroviral
drugs were not available in the public sector.
Laboratory methods
Wet mount preparations were used under microscopy for diagnosis
of Trichomonas vaginalis, Candida albicans and Bacteria
vaginosis. Syphilis was diagnosed with Rapid Reagin test and
conﬁrmed with Tissue Plasminogen Hemagglutination Assay
(Randox Laboratories, Crumlin, County Antrim, UK). Herpes
simplex type-2 was diagnosed with an Enzyme-linked Immunosorbent
Assay (Focus Diagnostics, Cypress, CA, USA). Infant blood samples
were processed and tested for HIV with DNA PCR (Roche Diagnostics,
Indianapolis, IN, USA) if the infants were less than 15 months of age,
and with rapid HIV antibody tests, Determine (Abbott Diagnostics,
Abbott Park, IL, USA) and Oraquick (Abbott Diagnostics) if 15 months
or older. Both the Determine and Oraquick tests were performed
for every sample taken at 15 months or older, and HIV DNA PCR
was used as a tie-breaker. A time interval of 15 months was selected
as the provisional exit for the study while waiting for the 18-month
routine vaccination visit for further conﬁrmation of infant HIV
results and missed exit visits.
7
Statistical analysis
Baseline descriptions of maternal sociodemographic characteristics
were compared between mothers who transmitted HIV and those
who did not. w
2-tests and relative risks for mother-to-child
transmission were calculated for sexually transmitted infections,
infant characteristics and maternal baseline full blood counts.
Thereafter, factors that had a P-value of less than 0.25 in the
univariate analysis were included in multivariate analysis to
control for confounding and to identify the most important risk
factors for HIV vertical transmission. The multivariate models were
run separately for maternal and infant risk factors.
Results
From the initial cohort of 479 HIV-infected pregnant women at
enrolment, 45 (9.4%) had no delivery information. Of the 434
remaining mother and infant pairs, 46 (10.6%) infants died
without any deﬁnitive HIV test result. A total of 281 (65%) had
a deﬁnitive HIV result by 15 months of age. Of these, 89 (31.7%)
infants became HIV infected by 15 months of age (Figure 1).
There were no signiﬁcant differences between the mothers who
transmitted HIV and those who did not transmit in terms of
maternal and partner’s age, gravidity, marital status, partner
circumcision status and risky behaviors, such as any maternal
alcohol consumption and vaginal herb use (Table 1). Table 2
considers some factors in the maternal WHO clinical staging of
AIDS. During the study period, HIV viral loads and CD4 counts were
not available in the public sector, and therefore the total
lymphocyte count is mentioned. There were no signiﬁcant
differences between the maternal total lymphocyte count,
hemoglobin, presence of axillary and/or cervical lymphadenopathy,
history of prolonged fever and diarrhea and presence of
tuberculosis in the past 5 years between HIV transmitters and non-
transmitters. Mothers whose breasts were abnormal at physical
479 HIV positive
pregnant women
enrolled into the study 
434 mother-infant pairs
45 with no delivery
information 
281 infants with a
definitive HIV result at
15 months
153 infants without a
definitive HIV result at
15 months 
89 (31.7%) HIV positive
infants at 15 months 
192 HIV negative infants
at 15 months 
Figure 1 Follow-up of HIV-infected women and their infants.
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Journal of Perinatologyexamination (swollen and tender, discharging pus), a possible
indicator of mastitis at enrolment, were twice as likely to be HIV
vertical transmitters, 61.5 vs 30.0% (risk ratio 2.07 (1.28 to 3.32).
Maternal death during the 15-month follow-up period was a
predictor of vertical transmission (Table 2).
There were signiﬁcant differences between the HIV vertical
transmitters and the non-transmitters on the presence of abnormal
vaginal discharge, genital itchiness, genital ulcers and dysuria
(Table 3). However, physical examination conﬁrmation of genital
ulcer disease was not statistically different. When the types of
abnormal vaginal discharge were considered individually, that is,
yellow, gray and curd-like, there were no statistical differences
between the two groups. The conﬁrmed presence of vaginal
infections, namely, T. vaginalis, B. vaginosis and C. albicans
in the mother at enrolment, was associated with HIV vertical
transmission (Table 3) and it remained a risk after multivariate
analysis of all maternal factors with a risk ratio of 1.72
(1.03 to 2.88).
When we examined infant characteristics by HIV status, low
birth weight infants and those who subsequently died during
follow-up were more likely to be HIV infected (Table 4).
Breastfeeding was not a statistically signiﬁcant risk factor for being
HIV infected. The median duration of exclusive breastfeeding was
low in these two groups and was not signiﬁcantly different
between the transmitters (3 months (interquartile range 2; 6)
and non-transmitters (4 months (interquartile range 2; 6). Forty
percent of mother–infant pairs who did not receive nevirapine
transmitted HIV compared with 30% of those who received
nevirapine. We controlled for potential confounding with a
multivariate analysis of risk factors of HIV vertical transmission
(Table 5). After controlling for other maternal factors (signs and
symptoms of sexually transmitted infections, conﬁrmed vaginal
infections and proxy maternal disease stage as indicated by
maternal mortality during the study period), mothers with
abnormal breasts at enrolment were four times more likely to
transmit HIV (risk ratio 4.16 (1.10 to 15.9).
Discussion
Our ﬁnding that vaginal infections in HIV-infected pregnant
women in the last trimester are a risk of HIV vertical transmission
is important. The infections, namely, C. albicans, T. vaginalis and
B. vaginosis, double the risk. There is paucity of data on these
ﬁndings, but in a study by Fawzi et al.,
2 gonorrhea was found to be
related to intrauterine transmission. A possible biological
explanation is that these infections can be associated with
chorioamnionitis, increased viral shedding in secretions and
inﬂammatory cytokine production, which facilitate HIV
transmission.
8 This study was performed at low-risk peripheral
clinics where all women delivered vaginally. An increased risk of
perinatal HIV transmission among herpes simplex virus type-2
seropositive women and an increased risk of intrapartum HIV
transmission among women shedding herpes simplex type-2 were
reported by Bollen et al.
9
Mastitis has been reported to increase the risk of breastfeeding
transmission.
10–12 There is paucity of information on antenatal
mastitis in HIV-infected women. In our study, the presence of
abnormal breasts at about 36 weeks’ gestation, which was a proxy
for mastitis, was associated with a four times risk of HIV vertical
transmission. Breastfeeding infants at 6 weeks of age were three
times more likely to be HIV infected after multivariate analysis,
although this was not statistically signiﬁcant with a wide
conﬁdence interval. The trend of the adjusted risk ratios becomes
more precise by 9 months of age. When feeding replacements are
affordable and the practice is feasible, alternative foods are
preferred to breast milk. The women were counseled to stop
breastfeeding at 6 months, if feasible, but a signiﬁcant proportion
continued breastfeeding up to 9 months and beyond. Breastfeeding
is a major health-promoting factor for infants and children in
Table 1 Comparison of maternal sociodemographic characteristics of
HIV-infected mothers by infant HIV transmission
Factor HIV
Transmitters
Non-
transmitters
Risk ratio
(95% CI)
Maternal age N¼192 N¼89
Mean (s.d.) 26.24 (4.85) 26.91 (5.02) 1.02 (0.98–1.06)
Gravidity N¼189 N¼87
Primigravid 36 (72.0%) 14 (28.0%) 1.15 (0.71–1.87)
Multiparous 153 (67.7%) 73 (32.3%)
Married N¼173 N¼83
No 25 (64.1%) 14 (35.9%) 1.13 (0.71–1.79)
Yes 148 (68.2%) 69 (31.8%)
Partners age N¼179 N¼80
Mean (s.d.) 33.55 ( (7.67) 33.98 (6.77) 1.01 (0.98–1.03)
Vaginal herbs use N¼188 N¼89
No 152 (66.7%) 76 (33.3%) 0.70 (0.41–1.22)
Yes 36 (76.6%) 11 (23.4%)
Circumcised partner N¼137 N¼64
No 115 (67.7%) 55 (32.3%) 0.90 (0.50–1.62)
Yes 22 (71.0%) 9 (29.0%)
Any maternal alcohol
consumption
N¼185 N¼86
No 176 (69.3%) 78 (30.7%) 1.53 (0.9–2.62)
Yes 9 (53.0%) 8 (47.1%)
Abbreviations: CI, conﬁdence interval; HIV, human immunodeﬁciency virus.
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Journal of Perinatologydeveloping countries, but the risk of MTCT of HIV by this route is
challenging traditional practices and health policies in low
resource countries.
13 Exclusive breastfeeding has been found to
reduce transmission relative to mixed feeding.
14 In our study, the
median duration of exclusive breastfeeding in HIV-infected infants
was only 3 months after our mothers were counseled about the
beneﬁts of exclusive breast feeding.
Deaths of infants and mothers during follow-up were associated
with infant HIV infection. Maternal death implies advanced AIDS
and higher viral loads, which we were unable to measure because
of resource constraints at the time of the study. It is known that
HIV-infected infants are at increased risk of mortality particularly
in the ﬁrst year of life, and hence the need to offer them early
treatment.
15
In a study by Bobat et al.,
16 low hemoglobin during pregnancy
deﬁned by hemoglobin of less than 10g per 100ml was associated
with an increased risk of HIV vertical transmission. This ﬁnding
was not evident in our study. In the same study, a positive syphilis
serology was not associated with vertical transmission.
16 Our
ﬁnding, which grouped positive serology for herpes simplex type-2
and syphilis because of the few cases of positive syphilis serology,
had similar results.
Low birth weight has been found to be associated with in utero
HIV transmission.
17 Our low birth weight was unlikely to be
inﬂuenced by prematurity because recruitment of the mothers
occurred from 36 weeks’ gestational age. However, with the control
of breastfeeding and nevirapine intake, it dropped from statistical
signiﬁcance.
Despite our ﬁndings of increased vertical HIV transmission
associated with maternal genital infections, breastfeeding and
mastitis, our study is not without limitations. First, this study was
not a randomized trial but a prospective cohort, and thus any of
the ﬁndings may be inaccurate because of confounding bias.
Further, we did not have complete follow-up of the women and
Table 2 Comparison of maternal clinical characteristics at enrolment by HIV vertical transmission
Characteristic HIV Transmitters HIV Non-transmitters Risk ratio (95% CI)
Maternal total lymphocyte count N¼61 N¼106
Mean (s.d.) 2.28 (0.98) 2.16 (1.06) 1.06 (0.85–1.33)
Maternal hemoglobin N¼89 N¼192
X10g per 100ml 79 (31.1%) 175 (68.9%) 1.19 (0.70–2.01)
<10g per 100ml 10 (37.0%) 17 (63.0%)
Maternal generalized lymphadenopathy N¼63 N¼151
No 53 (28.7%) 132 (71.4%) 1.20 (0.69–2.09)
Yes 10 (34.5%) 19 (65.5%)
History of prolonged fever (>2 weeks) N¼88 N¼190
No 83 (31.2%) 183 (68.8%) 1.34 (0.67–2.67)
Yes 5 (41.7%) 7 (58.3%)
History of prolonged diarrhea (>1 month) N¼89 N¼190
No 85 (31.5%) 185 (68.5%) 1.41 (0.67–3.00)
Yes 4 (44.4%) 5 (55.6%)
History of tuberculosis N¼88 N¼188
No 84 (32.0%) 178 (67.9%) 0.89 (0.38–2.08)
Yes 4 (28.6%) 16 (71.4%)
Abnormal breast at enrolment
a N¼72 N¼156
No 64 (30.0%) 151 (70.3%) 2.07 (1.28–3.32)
Yes 8 (61.5%) 5 (38.5%)
Deceased mother during follow-up N¼89 N¼192
No 85 (30.7%) 192 (69.3%) 3.26 (2.73–3.89)
Yes 4 (100.0%) 0 (0.0%)
Abbreviations: CI, conﬁdence interval; HIV, human immunodeﬁciency virus.
aAbnormal breast¼swollen and tender and/or discharging pus.
Risk factors of HIV vertical transmission
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Journal of Perinatologyinfants in the study, which may lead to bias as well. For some of
the predictors of HIV transmission that we examined, we were
inadequately powered, particularly with few non-breastfed infants
and few mother and child pairs who did not receive nevirapine.
This study cannot be generalized to other settings without similar
breastfeeding practices and a high prevalence of HIV similar to ours.
In conclusion, in resource-limited communities with HIV-
infected pregnant women who opt to breastfeed, there is a need
Table 3 Comparison of maternal sexual transmitted infections risk factors at enrolment by HIV vertical transmission
Factors HIV Transmitters HIV Non-transmitters Risk ratio
(95% CI)
Prior vaginal discharge treatment N¼88 N¼191
No 65 (33.7%) 128 (66.3%) 0.79 (0.53–1.19)
Yes 23 (26.7%) 63 (73.3%)
Prior genital ulcer treatment N¼88 N¼190
No 75 (32.2%) 158 (67.8%) 0.90 (0.55–1.47)
Yes 13 (28.9%) 32 (71.1%)
Vaginal discharge at enrolment N¼89 N¼190
No 60 (28.7%) 149 (71.3%) 1.44 (1.02–2.05)
Yes 29 (41.4%) 41 (58.6%)
Genital itch at enrolment N¼89 N¼190
No 51 (27.7%) 133 (72.3%) 1.44 (1.03–2.03)
Yes 38 (40.0%) 57 (60.0%)
Genital ulcer at enrolment N¼89 N¼189
No 73 (29.8%) 172 (70.2%) 1.63 (1.09–2.43)
Yes 16 (48.5%) 17 (51.5%)
Dysuria at enrolment N¼89 N¼189
No 73 (29.7%) 173 (70.3%) 1.68 (1.13–2.50)
Yes 16 (50.0%) 16 (50.0%)
Partner have genital ulcer disease N¼84 N¼178
No 73 (30.4%) 167 (69.6%) 1.64 (1.04–2.60)
Yes 11 (50.0%) 11 (50.0%)
Partner have urethral discharge N¼84 N¼177
No 78 (31.7%) 168 (68.3%) 1.26 (0.66–2.41)
Yes 6 (40.0%) 9 (60.0%)
Clinical genital ulcer disease N¼53 N¼116
No 49 (30.3%) 113 (69.8%) 1.89 (0.96–3.74)
Yes 4 (57.1%) 3 (42.9%)
HSV2/syphilis serology positive N¼61 N¼125
No 5 (18.5%) 22 (81.5%) 1.90 (0.84–4.31)
Yes 56 (35.2%) 103 (64.8%)
Vaginal infections combined
a N¼60 N¼129
No 35 (25.0%) 105 (75.0%) 2.04 (1.37–3.04)
Yes 25 (51.0%) 24 (49.0%)
Abbreviations: CI, conﬁdence interval; HIV, human immunodeﬁciency virus; HSV2, herpes simplex virus type-2.
aVaginal infections: T. vaginalis, B. vaginosis and C. albicans.
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Journal of Perinatologyto consider vaginal infection screening, particularly T. vaginalis,
B. vaginosis and C. albicans, and examination of women
for possible mastitis to identify women at risk of HIV
vertical transmission. This enables them to have early treatment,
which could protect the infant. Small-for-dates HIV-infected
pregnant women and low birth weight infants need special
attention and early management. Early infant diagnosis
and management of HIV-infected infants are priorities to
reduce mortality.
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Table 4 Comparison of infant characteristics by infant HIV-infection status
Characteristics HIV-positive infants HIV-negative infants Risk ratio (95% CI)
Mother and baby nevirapine N¼79 N¼168
No 19 (39.6%) 29 (60.4%) 0.76 (0.51–1.15)
Yes 60 (30.2%) 139 (69.9%)
Infant sex N¼76 N¼167
Male 45 (35.4%) 82 (64.6%) 1.32 (0.90–1.94)
Female 31 (26.7%) 85 (68.7%)
Infant delivery weight N¼85 N¼178
X2500g 73 (30.2%) 169 (69.8%) 1.89 (1.25–2.87)
<2500g 12 (57.1%) 9 (42.9%)
Breastfeeding at 6 weeks N¼80 N¼181
No 6 (18.2%) 27 (81.8%) 1.86 (0.82–4.21)
Yes 74 (32.5%) 154 (67.5%)
Breastfeeding at 4 months N¼59 N¼167
No 5 (14.7%) 29 (85.3%) 1.91 (0.83–4.43)
Yes 54 (28.1%) 138 (71.9%)
Breastfeeding at 9 months N¼42 N¼142
No 12 (16.4%) 61 (83.6%) 1.64 (0.90–3.00)
Yes 30 (27.0%) 81 (73.0%)
Median duration exclusive breastfeeding (months) (interquartile range) N¼49 N¼118
3 (2;6) 4 (2;6) 0.88 (0.70–1.09)
Infant deceased during follow-up N¼89 N¼192
No 49 (20.9%) 185 (79.1%) 4.06 (3.08–5.36)
Yes 40 (85.1%) 7 (14.9%)
Abbreviations: CI, conﬁdence interval; HIV, human immunodeﬁciency virus.
Table 5 Multivariate analysis of predictors of HIV vertical transmission
Risk factor Risk ratio (95% CI)
Vaginal infections
a 1.72 (1.03–2.88)
Serologic STI (syphilis, HSV2) 1.64 (0.43–6.29)
Mother deceased during follow-up 4.16 (1.10–15.9)
Clinical genital ulcer 1.08 (0.44–2.66)
Abnormal breast
b 4.36 (2.89–6.58)
Have dysuria 1.51 (0.80–2.86)
Have genital itch 1.25 (0.66–2.30)
Have vaginal discharge 0.93 (0.49–1.78)
Mother and infant nevirapine intake 0.90 (0.45–1.75)
Infant delivery weight 1.34 (0.62–2.88)
Breastfeeding at 6 weeks 3.04 (0.22–42.02)
Breastfeeding at 4 months 1.06 (0.15–7.28)
Breastfeeding at 9 months 1.67 (0.79–3.52)
Abbreviations: CI, conﬁdence interval; HIV, human immunodeﬁciency virus; HSV2, herpes
simplex virus type-2.
aVaginal infections: T. vaginalis; B. vaginosis and C. albicans.
bAbnormal breast¼swollen and tender and/or discharging pus.
Risk factors of HIV vertical transmission
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